US-based pharmaceutical company Johnson & Johnson (NYSE:JNJ) announced on Sunday new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy.

Findings from the first-in-human study demonstrate that pasritamig appears well-tolerated and exhibits a promising anti-tumour activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.

The results were featured in an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology.

Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2 -- a prostate-specific antigen with minimal expression outside of the prostate.